Biotechnology Stocks on Investors' Radar -- Minerva Neurosciences, Portola Pharma, Trevena, and Anthera Pharma

Aug 02, 2016, 10:02 ET from Chelmsford Park SA

NEW YORK, August 2, 2016 /PRNewswire/ --

The Biotech stocks are showing substantial strength as on Monday, August 01st, 2016, the NYSE Arca Biotechnology Index was up 2.7%, reaching a seven-month intra-day high. now assesses the following equities and see how they fared at the last close: Minerva Neurosciences Inc. (NASDAQ: NERV), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Trevena Inc. (NASDAQ: TRVN), and Anthera Pharmaceuticals Inc. (NASDAQ: ANTH). Learn more about these stocks by downloading their comprehensive and free reports at:

Minerva Neurosciences  

On Monday, shares in Waltham, Massachusetts-based Minerva Neurosciences Inc. recorded a trading volume of 173,531 shares. The stock ended the day at $11.18, climbing 0.72%. The Company's shares have gained 9.50% in the last one month, 76.90% over the previous three months, and 84.18% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 8.99% and 67.20%, respectively. Furthermore, shares of Minerva Neurosciences, which focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases, have a Relative Strength Index (RSI) of 48.38.

On July 28th, 2016, Minerva Neurosciences announced that it will release its financial results and business updates for Q2 2016 on August 4th, 2016. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. NERV complete research report is just a click away and free at:

Portola Pharma  

South San Francisco, California headquartered Portola Pharmaceuticals Inc.'s stock finished yesterday's session 2.77% higher at $26.68. A total volume of 850,154 shares was traded, which was above their three months average volume of 639,190 shares. The Company's shares have gained 13.05% in the last one month and 9.12% over the previous three months. The stock is trading above its 50-day moving average by 6.70%. Furthermore, shares of Portola Pharmaceuticals, which develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation, have an RSI of 65.98. The complimentary report on PTLA can be downloaded at:


At the closing bell on Monday, shares in King of Prussia, Pennsylvania-based Trevena Inc. rose 1.91%, ending the day at $6.39. The stock recorded a trading volume of 368,550 shares. The Company's shares have advanced 1.43% in the last one month and are trading 5.25% below their 50-day moving average. Moreover, shares of Trevena, which discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors, have an RSI of 41.52. Sign up for your complimentary research report on TRVN at:

Anthera Pharma  

Hayward, California headquartered Anthera Pharmaceuticals Inc.'s stock ended the day 0.97% lower at $3.05, with a total volume of 422,965 shares traded. Shares of the Company, which focuses on the development and commercialization of medicines for patients with unmet medical needs, are trading 8.49% below their 50-day moving average. The stock has an RSI of 38.30.

On June 28th, 2016, Anthera Pharmaceuticals announced results from interim analysis of the Phase 2 BRIGHT-SC proof-of-concept study in 57 patients with biopsy-proven IgA Nephropathy. Additionally, the company announced that its Phase 3 SOLUTION clinical study with Sollpura® has closed screening and that the first patients in the Phase 3 CHABLIS 7.5 clinical study with blisibimod have been screened. The company reported that interim data from the BRIGHT-SC study (n=57) demonstrated a positive trend in the reduction of proteinuria in blisibimod versus placebo treated patients. Additionally, secondary biomarker data from the study, including changes in total B cell counts and changes in immunoglobulins IgA, IgG, and IgM, were highly consistent with previous studies with blisibimod and demonstrated marked reduction after 8 weeks on study.  As a result of the increasing proteinuria effect after 24-week of dosing, and the clear demonstration of blisibimod's effect on immunological markers relevant to IgA nephropathy, the company has elected to continue the study through the 48-week time-point.

On July 08th, 2016, research firm H.C. Wainwright initiated a 'Buy' rating on the Company's stock, issuing a target price of $10 per share. Get free access to your research report on ANTH at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA